Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Phase II Study of Combination of the Hypercvad Regimen with Dasatinib in the Front Line Therapy of Patients with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL).

Farhad Ravandi, MD, Hagop M. Kantarjian, MD, Deborah A. Thomas, MD, Stefan Faderl, MD, Dan Jones, MD, PhD, Charles A Koller, MD, Samuel Dara, Rebecca Garris, Partow Kebriaei, MD, Richard Champlin, MD, Gautam Borthakur, MD, William G. Wierda, M.D., Ph.D, Jan A. Burger, MD, PhD, Jorge Cortes, MD, Susan O'Brien

Blood (2009) 114 (22): 837.

https://doi.org/10.1182/blood.V114.22.837.837

Published: 2009

Journal Articles

Acute Erythroleukemia: An Analysis of 108 Patients Treated with Cytarabine-Containing Regimens at the M.D. Anderson Cancer Center.

Fabio P.S. Santos, MD, Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Charles A. Koller, MD, Miloslav Beran, MD, PhD, Gautam Borthakur, MD, Carlos Bueso-Ramos, MD, PhD, Michael Keating, MB, BS, Jorge Cortes, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD

Blood (2008) 112 (11): 925.

https://doi.org/10.1182/blood.V112.11.925.925

Published: 2008

Journal Articles

Outcome after Frontline Therapy with the Modified Hyper-CVAD Regimen with or without Rituximab for De Novo Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL).

Deborah A. Thomas, MD, Hagop Kantarjian, MD, Stefan Faderl, MD, William G. Wierda, M.D., Ph.D, Alessandra Ferrajoli, MD, Jan A. Burger, MD, PhD, Jorge Cortes, MD, Charles A. Koller, MD, Gautam Borthakur, MBBS, Zeev Estrov, Marina Konopleva, MD, PhD, Farhad Ravandi, MBBS, Guillermo Garcia- Manero, MD, Susan O’Brien, M.D.

Blood (2008) 112 (11): 1931.

https://doi.org/10.1182/blood.V112.11.1931.1931

Published: 2008

Journal Articles

Intensification of Hyper-CVAD with L-Asparaginase, Vincristine, and Dexamethasone ("Augmented Hyper-CVAD") Has Activity in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL).

Stefan Faderl, MD, Deborah A. Thomas, MD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Miloslav Beran, MD PhD, Michael Rytting, MD, Charles A. Koller, MD, Srdan Verstovsek, MD PhD, Gautam Borthakur, MD, Michael Andreeff, MD PhD, Steve Kornblau, MD, Susan O’Brien, MD, Khanh Vu, MD, Monica Kwari, RN, Jennie Bretz, RN, Hagop M. Kantarjian, MD

Blood (2007) 110 (11): 4324.

https://doi.org/10.1182/blood.V110.11.4324.4324

Published: 2007

Journal Articles

Final Update of Phase I-II Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with Idarubicin and Cytarabine for Patients with Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome.

John Delmonte, Jr., MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Zeev Estrov, MD, Farhad Ravandi, MD, Srdan Verstovsek, MD/PhD, Susan O’Brien, MD, Charles A. Koller, MD, Stefan Faderl, MD, Deborah A. Thomas, MD, John J. Wright, MD, Jorge Cortes, MD

Blood (2007) 110 (11): 441.

https://doi.org/10.1182/blood.V110.11.441.441

Published: 2007

Journal Articles

Phase II Study of Thymglobulin, Cyclosporin, and G-CSF for the Initial Treatment of Aplastic Anemia and Low Risk Myelodysplastic Syndrome.

Farhad Ravandi-Kashani, MD, Zeev Estrov, MD, Alessandra Ferrajoli, MD, Gautam Borthakur, MD, Miloslav Beran, MD, Sherry Pierce, RN, Charles A. Koller, MD, Jorge Cortes, MD, Stefan Faderl, MD, Hagop M. Kantarjian, MD

Blood (2006) 108 (11): 4830.

https://doi.org/10.1182/blood.V108.11.4830.4830

Published: 2006

Journal Articles

Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia (ALL): The MDACC Experience with Intensified L-Asparaginase and Vincristine in Adult ALL Salvage.

Stefan Faderl, MD, Deborah A. Thomas, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MD, Miloslav Beran, MD, PhD, Michael Rytting, MD, Charles A. Koller, MD, Srdan Verstovsek, MD, PhD, Gautam Borthakur, MD, Michael Andreeff, MD, PhD, Steve Kornblau, MD, Khanh Vu, MD, Rita Jarmon, R.N., Hagop M. Kantarjian, MD

Blood (2005) 106 (11): 1840.

https://doi.org/10.1182/blood.V106.11.1840.1840

Published: 2005

Journal Articles

Increased Bone Marrow Erythroid Precursors Is Associated with Shorter Survival in Low-Grade Myelodysplastic Syndromes.

Hesham M. Amin, MD, MSc, Sherry A. Pierce, RN, Hagop M. Kantarjian, MD, Michael J. Keating, MD, Emil J. Freireich, MD, Charles A. Koller, MD, Miloslav Beran, MD, PhD, Maher Albitar, MD, Susan M. O’Brien, MD, Elihu H. Estey, MD

Blood (2004) 104 (11): 2371.

https://doi.org/10.1182/blood.V104.11.2371.2371

Published: 2004

NARROW

Phase II Study of Combination of the Hypercvad Regimen with Dasatinib in the Front Line Therapy of Patients with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL).

Acute Erythroleukemia: An Analysis of 108 Patients Treated with Cytarabine-Containing Regimens at the M.D. Anderson Cancer Center.

Outcome after Frontline Therapy with the Modified Hyper-CVAD Regimen with or without Rituximab for De Novo Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL).

Intensification of Hyper-CVAD with L-Asparaginase, Vincristine, and Dexamethasone ("Augmented Hyper-CVAD") Has Activity in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL).

Final Update of Phase I-II Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with Idarubicin and Cytarabine for Patients with Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome.

Phase II Study of Thymglobulin, Cyclosporin, and G-CSF for the Initial Treatment of Aplastic Anemia and Low Risk Myelodysplastic Syndrome.

Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia (ALL): The MDACC Experience with Intensified L-Asparaginase and Vincristine in Adult ALL Salvage.

Increased Bone Marrow Erythroid Precursors Is Associated with Shorter Survival in Low-Grade Myelodysplastic Syndromes.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only